AI Access Brief Podcast
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and evidence strategy.
AI Access Brief Podcast
Critical Medicines Act Shapes EU HTA Landscape
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
The Critical Medicines Act, provisional agreement on May 12th, changes the game. Combining regulatory tools with targeted industrial policy measures isn't just about supply chain resilience anymore.
SPEAKER_00Exactly, but look at the scope. Over 200 active substances on the union list of critical medicines. The MSSG is already evaluating vulnerabilities in supply chains for the first set. This isn't theoretical planning.
SPEAKER_01The preparedness angle is what catches my attention. When you're building systematic vulnerability assessment into the regulatory framework, you're essentially creating a new evidence requirement for market access.
SPEAKER_00And it's not just about shortages. The industrial policy component means we're looking at strategic manufacturing incentives tied to regulatory pathways. That shifts the commercial calculus for portfolio planning.
SPEAKER_01The timing with HTA implementation isn't coincidental. When the MSSG is evaluating vulnerabilities while JCA processes are scaling, you're creating parallel evidence streams that will intersect at reimbursement decisions.
SPEAKER_00Which brings us to a fundamental question about evidence hierarchy. How do supply chain resilience considerations weigh against traditional clinical and economic evidence in HTA decisions?
SPEAKER_01That's the unknown. But the provisional agreement suggests these won't be separate considerations. They're building industrial policy directly into the regulatory framework, which means it becomes part of the value proposition.
SPEAKER_00The next six months will show us how this translates into actual guidance for manufacturers. The framework is there, but the operational details determine whether this becomes a paperwork exercise or a real shift in market access strategy.
SPEAKER_01AII tag's data transparency principles adopted May 18th are more significant than they appear on first read. When you're scaling joint clinical assessments to potentially 35 cancer treatments, transparency isn't just good governance.
SPEAKER_00That's not tokenism anymore.
SPEAKER_01The translation into eight languages versus the initial target of five tells you something about demand. But here's my concern. Are we building patient involvement capacity faster than we're building robust processes to integrate that input?
SPEAKER_00That's exactly the right question. The EU 4 health funding for patient involvement projects suggests systematic investment, but the quality control mechanisms aren't clear yet.
SPEAKER_01When HTAG estimates 35 joint clinical assessments for cancer treatments and 15 for advanced therapy medicinal products, you're looking at massive coordination complexity. Patient input at that scale requires standardized processes, not ad hoc consultation.
SPEAKER_00And the medical devices component, approximately five joint clinical assessments starting June 2026. That's where patient involvement becomes even more complex. Device HTA requires different patient perspectives than drug HTA.
SPEAKER_01The guiding principles on data transparency should address some of this, but principles aren't processes. The real test is whether these transparency frameworks can handle the volume HTACG is projecting.
SPEAKER_00Especially when you consider that each joint clinical assessment involves multiple member states with different patient organization landscapes. Standardizing patient involvement across that diversity is a regulatory challenge we haven't solved yet.
SPEAKER_01EMA's clinical trial tracking shows 19 multinational trials authorized above historical average. That's concrete evidence the regulatory reforms are working, but it also highlights capacity pressures ahead.
SPEAKER_00Those numbers matter for HTA planning. More multinational trials mean more coordinated evidence generation, which should align better with joint clinical assessments. But it also means more complex evidence packages.
SPEAKER_01The Pharmacovigilance Risk Assessment Committee's May 4th. Seven activities included referrals on safety and benefit risk balance. When you're processing more trials with more complex international coordination, pharmacovigilance becomes a bottleneck.
SPEAKER_00But also an opportunity. Better international coordination and trial design should mean better safety data for HTA purposes. The question is whether the HTACG processes can leverage that improved data quality.
SPEAKER_01Here's where I see potential friction. The 2030 clinical trial targets are about volume and speed. Joint clinical assessments require depth and coordination. Those objectives don't automatically align.
SPEAKER_00Actually, I think they do align, but not in the way most people expect. The multinational trial coordination is creating standardized evidence packages that should feed more efficiently into joint assessments.
SPEAKER_01That assumes the trial design considerations match HTA evidence requirements. We've seen plenty of cases where regulatory approval data doesn't translate cleanly to HTA decisions.
SPEAKER_00Fair point. But the increased coordination between EMA and HTACG processes should reduce that gap. The real question is whether 19 additional multinational trials is sustainable momentum or a temporary spike.
SPEAKER_01Nice threshold changes to 25,000 pounds, 35,000 pounds per collie are now operational, and we're already seeing the impact. The Tisabri and biosimilar Taruco guidance for highly active relapsing remitting MS shows the new framework in action.
SPEAKER_00The semiglutide cardiovascular risk indication approval is equally telling. These aren't marginal cases, they're major therapeutic areas where the threshold shift changes market access fundamentals.
SPEAKER_01But here's what concerns me about the digital health technology framework evolution. The scoping review published March 9th found existing HTA frameworks may not address digital health complexities. We're raising cost-effectiveness thresholds while our evaluation methods are falling behind.
SPEAKER_00That's not necessarily a contradiction. The threshold increase gives us more room to approve technologies while we develop better evaluation methods. The alternative is rejecting digital innovations because our frameworks are inadequate.
SPEAKER_01I disagree. Higher thresholds with inadequate evaluation frameworks means we're essentially lowering evidence standards for digital technologies. That's not sustainable health economics.
SPEAKER_00But it's practical policy. The digital health technologies aren't waiting for perfect HTA frameworks. If we don't adapt our evaluation methods, we'll be making decisions based on completely inappropriate criteria.
SPEAKER_01The question is whether the threshold increase buys us time to develop better frameworks or just postpones the inevitable methodological reckoning. The scoping review suggests we're not even close to consensus on evaluation approaches.
SPEAKER_00Which is exactly why the threshold flexibility matters. We need space to experiment with different evaluation approaches for digital technologies without automatically rejecting everything that doesn't fit traditional models.
SPEAKER_01The Critical Medicines Act provisional agreement creates new market access variables just as HTA processes are scaling internationally that strategic complexity manufacturers haven't faced before.
SPEAKER_00And nice threshold changes are happening while digital health evaluation frameworks lag behind technological development. The next 12 months will test whether our regulatory adaptation can keep pace with innovation.
SPEAKER_01Back tomorrow, show notes at outcomes analytica.no.